biote Corp. (BTMD)
NASDAQ: BTMD
· Real-Time Price · USD
3.36
-0.18 (-5.08%)
At close: Apr 30, 2025, 10:07 AM
-5.08% (1D)
| Bid | 3.2 |
| Market Cap | 183.83M |
| Revenue (ttm) | 197.19M |
| Net Income (ttm) | 6.01M |
| EPS (ttm) | 0.09 |
| PE Ratio (ttm) | 37.33 |
| Forward PE | 5.79 |
| Analyst | Buy |
| Ask | 3.36 |
| Volume | 19,369 |
| Avg. Volume (20D) | 209,537 |
| Open | 3.53 |
| Previous Close | 3.54 |
| Day's Range | 3.29 - 3.53 |
| 52-Week Range | 3.04 - 8.44 |
| Beta | 1.18 |
About BTMD
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was fou...
Industry Medical - Care Facilities
Sector Healthcare
IPO Date Apr 28, 2021
Employees 217
Stock Exchange NASDAQ
Ticker Symbol BTMD
Website https://biote.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BTMD stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 138.10% from the latest price.
Stock ForecastsNext Earnings Release
biote Corp. is scheduled to release its earnings on May 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-25.12%
Biote shares are trading lower after the company r...
Unlock content with
Pro Subscription
8 months ago
-18.91%
Biote shares are trading lower after the company reported worse-than-expected Q2 EPS results.
